Note 5 — Restructuring and impairment charges

The following tables provide information regarding restructuring and impairment charges recognized by the Company for the three and six months ended July 1, 2018 and July 2, 2017:



Three Months Ended July 1, 2018
	Termination benefits		Other costs ₍₂₎		Total
	(Dollars in thousands)
2018 Footprint realignment plan	$	52,345	$	129	$	52,474
Other restructuring programs ₍₁₎	574		440		1,014
Restructuring charges	$	52,919	$	569	$	53,488
Long-lived asset impairment charge	—		1,865		1,865
Restructuring and impairment charges	$	52,919	$	2,434	$	55,353



Three Months Ended July 2, 2017
	Termination benefits		Other costs ₍₂₎		Total
	(Dollars in thousands)
Restructuring charges ₍₃₎	$	612	$	258	$	870



Six Months Ended July 1, 2018
	Termination benefits		Other costs ₍₂₎		Total
	(Dollars in thousands)
2018 Footprint realignment plan	$	52,345	$	129	$	52,474
2016 Footprint realignment plan	2,199		291		2,490
Other restructuring programs ₍₄₎	1,032		555		1,587
Restructuring charges	$	55,576	$	975	$	56,551
Long-lived asset impairment charge	—		1,865		1,865
Restructuring and impairment charges	$	55,576	$	2,840	$	58,416



Six Months Ended July 2, 2017
	Termination benefits		Other costs ₍₂₎		Total
	(Dollars in thousands)
Vascular Solutions integration program	$	4,853	$	34	$	4,887
2017 EMEA restructuring program	6,536		—		6,536
2016 Footprint realignment plan	825		76		901
Other restructuring programs ₍₅₎	1,147		344		1,491
Restructuring charges	$	13,361	$	454	$	13,815


(1)	Other restructuring programs include the 2016 and 2014 Footprint realignment plans, the Vascular Solutions integration program and the 2017 EMEA restructuring program as well as the other 2016 restructuring programs.


(2)	Other costs include facility closure, contract termination, and other exit costs.

(3)

Restructuring charges include charges related to the Vascular Solutions integration program, 2017 EMEA restructuring program, the 2016 and 2014 footprint realignment plans, the 2017 Pyng integration program and the 2016 Other Restructuring programs. The Company committed to the 2017 Pyng integration program, which relates to the integration of Pyng Medical Corp. (“Pyng”) into the Company, during the second quarter of 2017, following the Company’s acquisition of Pyng in April 2017.

(4) Other restructuring programs include the 2014 Footprint realignment plan, Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs.

(5) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Pyng integration program and the 2016 Other Restructuring programs.

2018 Footprint Realignment Plan

On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain European manufacturing operations to an existing lower-cost location, the outsourcing of certain of the Company’s European distribution operations, and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2024. The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan:



Type of expense	Total estimated amount expected to be incurred
Termination benefits	$60 million to $70 million
Other exit costs ₍₁₎	$2 million to $4 million
Restructuring charges	$62 million to $74 million
Restructuring related charges ₍₂₎	$40 million to $59 million
Total restructuring and restructuring related charges	$102 million to $133 million


(1)	Includes contract termination, facility closure, employee relocation, equipment relocation and outplacement costs.

(2)

Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new location, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold.

In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2018 Footprint realignment plan of $1.0 million for the three and six months ended July 1, 2018 within cost of goods sold.

As of July 1, 2018, the Company has a restructuring reserve of $51.4 million related to this plan, all of which related to termination benefits.

2016 Footprint Realignment Plan

In 2016, the Company initiated a restructuring plan (the “2016 Footprint realignment plan") involving the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018.

In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2016 Footprint realignment plan of $2.0 million and $3.3 million for the three and six months ended July 1, 2018 and $2.0 million and $4.1 million for the three and six months ended July 2, 2017, respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations.

The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 Footprint realignment plan of approximately $43 million. As of July 1, 2018, the Company has incurred aggregate restructuring charges in connection with the 2016 Footprint realignment plan of $17.1 million. Additionally, as of July 1, 2018, the Company has incurred aggregate restructuring related charges of $18.0 million with respect to the 2016 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of July 1, 2018, the Company has a restructuring reserve of $6.3 million related to this plan, all of which related to termination benefits.

2014 Footprint Realignment Plan

In 2014, the Company initiated a restructuring plan (“the 2014 Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 Footprint realignment plan of approximately $46 million to $51 million.

In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of $0.6 million and $1.0 million for the three and six months ended July 1, 2018, respectively, and $0.5 million and $2.1 million for the three and six months ended July 2, 2017, respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations.

As of July 1, 2018, the Company has incurred restructuring charges in connection with the 2014 Footprint realignment plan aggregating to $12.2 million. Additionally, as of July 1, 2018, the Company has incurred restructuring related charges aggregating to $27.9 million related to the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of July 1, 2018, the Company has a restructuring reserve of $3.9 million in connection with the plan, all of which related to termination benefits.

As the restructuring programs progress, management will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP. For a description of the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017.

Restructuring charges by reportable operating segment, and by all other operating segments in the aggregate, for the three and six months ended July 1, 2018 and July 2, 2017 are set forth in the following table:



	Three Months Ended					Six Months Ended
	July 1, 2018		July 2, 2017			July 1, 2018		July 2, 2017
	(Dollars in thousands)
Vascular North America	$	202	$	353		$	523	$	1,081
Interventional North America	362		191			907		4,406
Anesthesia North America	91		564			125		811
EMEA	52,539		(412		)	52,790		7,115
All other	294		174			2,206		402
Restructuring charges	$	53,488	$	870		$	56,551	$	13,815